#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15456	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2080	736.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	925	C,T	856,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28558	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3520	808.6	0	.	n	.	0	T695C	SNP	695	695	T	981	981	C	872	C,T	806,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28558	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3520	808.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1623	1623	A	940	A	865	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28558	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3520	808.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2257	2257	C	896	C,T	826,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28558	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3520	808.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2331	2331	A	875	A,T	831,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28558	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3520	808.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2883	2883	C	878	C	820	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2108	folP	855	855	100.0	folP.l15.c4.ctg.1	1504	139.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1013	1015	AGC	216;215;212	A;G;C	203;200;196	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5948	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3383	175.2	1	SNP	p	S91F	1	.	.	271	273	TTC	596	598	TTC	227;228;227	T;T,C;C	214;212,1;210	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5948	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3383	175.2	1	SNP	p	D95G	1	.	.	283	285	GGC	608	610	GGC	220;223;224	G;G,A;C	204;205,1;208	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5948	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3383	175.2	1	SNP	p	G95N	0	.	.	283	285	GGC	608	610	GGC	220;223;224	G;G,A;C	204;205,1;208	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1826	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1325	137.3	1	SNP	p	G45D	0	.	.	133	135	GGC	535	537	GGC	211;215;214	G,T;G;C,T	192,1;196;197,2	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	956	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	884	107.1	0	.	n	.	0	A197.	DEL	197	197	A	528	528	A	217	A	204	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5414	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3069	175.7	1	SNP	p	D86N	0	.	.	256	258	GAC	598	600	GAC	215;218;220	G;A;C	203;203;210	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5414	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3069	175.7	1	SNP	p	R87W	0	.	.	259	261	CGT	601	603	CGT	220;222;222	C;G,A;T	208;209,1;209	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5414	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3069	175.7	1	SNP	p	R87I	0	.	.	259	261	CGT	601	603	CGT	220;222;222	C;G,A;T	208;209,1;209	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5414	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3069	175.7	1	SNP	p	S87R	1	.	.	259	261	CGT	601	603	CGT	220;222;222	C;G,A;T	208;209,1;209	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5414	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3069	175.7	1	SNP	p	S88P	0	.	.	262	264	TCC	604	606	TCC	222;225;224	T;C;C	207;212;211	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4670	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2515	184.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1481	1483	GGC	227;225;224	G;G;C	207;203;203	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1230	1232	GCA	228;231;233	G;C;A	210;210;216	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1233	1235	ATC	236;238;242	A;T;C	219;222;223	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1245	1247	GTG	243;247;249	G;T;G	226;229;230	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1245	1247	GTG	243;247;249	G;T;G	226;229;230	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1749	1751	ACC	224;221;222	A;C;C	196;199;199	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1803	1805	GCG	194;194;193	G,C;C;G	166,1;150;153	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1803	1805	GCG	194;194;193	G,C;C;G	166,1;150;153	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1926	1928	GGC	170;168;172	G;G;C	155;154;157	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1935	1937	GGC	170;167;164	G;G;C	156;155;149	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4102	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2420	168.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1953	1955	CCG	141;146;141	C,G;C;G	98,8;104;96	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5802	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3110	185.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1704	1706	CCG	212;213;215	C;C;G	192;194;188	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2468	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1690	145.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	533	533	C	189	C	175	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	A29V	NONSYN	85	87	GCC	375	377	GTC	243;247;246	G;T,G;C,T	231;229,1;232,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	Y39H	NONSYN	115	117	TAC	405	407	CAC	244;240;241	C;A;C	224;217;222	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	T50A	NONSYN	148	150	ACT	438	440	GCT	241;241;246	G;C;T	220;220;222	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	K88L	NONSYN	262	264	AAA	552	554	CTC	234;233;231	C;T;C	219;217;217	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	S93N	NONSYN	277	279	AGC	567	569	AAC	245;245;246	A;A;C	221;220;225	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	H111R	NONSYN	331	333	CAT	621	623	CGT	248;249;250	C,A;G;T	228,1;229;228	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	N114S	NONSYN	340	342	AAC	630	632	AGC	246;245;244	A;G;C	231;226;227	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	I115V	NONSYN	343	345	ATC	633	635	GTC	241;241;238	G;T;C	223;220;223	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	L132S	NONSYN	394	396	TTG	684	686	TCG	207;207;208	T;C;G	192;191;191	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	Y201F	NONSYN	601	603	TAC	891	893	TTC	252;249;252	T;T;C	233;230;236	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	S236R	NONSYN	706	708	AGC	996	998	CGC	216;218;214	C;G;C	198;200;196	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	A249T	NONSYN	745	747	GCT	1035	1037	ACT	204;204;205	A;C;T	192;192;194	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2720	porB1a	984	984	98.17	porB1a.l15.c17.ctg.1	1418	190.2	0	.	p	.	0	A251V	NONSYN	751	753	GCG	1041	1043	GTG	215;215;211	G;T;G	203;203;200	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10692	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4981	214.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1094	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1141	95.3	1	SNP	p	V57M	1	.	.	169	171	ATG	499	501	ATG	238;241;241	A;T;G	220;222;223	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
